ABD sold more than 3.6 million cases in October. That is a strong start to the December quarter, though the latest financial results show why shareholders need to look beyond sales volumes.

Allied Blenders and Distillers (NSE: ABDL) has followed a record September with an even bigger October. Sales exceeded 3.6 million cases last month, compared with more than 3.5 million in September, according to its 4 November 2026 announcement. Together, the two months contributed more than seven million cases. The release appeared in the 11am–12pm exchange window.

For shareholders, this is welcome evidence that the September quarter’s demand has carried into Q3 FY27. It comes with a qualification, however. In Q2, income from operations rose 15.8%, while profit after tax increased 9.7%. Selling more has helped ABD grow, but the earnings benefit has been smaller than the sales headline suggests.

Analysis date: 4 November 2026. Financial figures below refer to consolidated Q2 and H1 FY27; market data are dated 3 November.

October gives ABD a strong start to Q3 FY27

To put October in context, ABD sold 10 million cases during the entire September quarter. One month has therefore delivered more than 36% of that volume, calculated from the rounded disclosures. It is a useful indication of the pace of business. It would be a mistake to turn it into a three-month forecast.

Festive demand helped both September and October, the company says. The monthly update does not show how much of the increase came from consumer purchases, distributor stocking or the timing of shipments. Nor does it provide revenue or profit for October. We will need the quarterly numbers to see how much of the volume translates into earnings.

ABD also reported that Officer’s Choice Brandy and Sumo Whisky had joined its millionaire-brand portfolio, bringing the total to six. Management attributed the wider sales performance to its core brands, market reach and contributions from domestic, defence and international channels.

A broader portfolio gives ABD more products to sell through its distribution network. Whether that makes the network more profitable depends on what it costs to establish those brands and persuade customers to buy them again.

Q2 margins explain the caution

The contrast between gross margin and EBITDA margin deserves attention. ABD retained more after product costs, but spent enough elsewhere to leave a smaller operating margin. Management points to planned investment in employees, established brands and the newer luxury portfolio.

Those expenses may support future growth. Shareholders still need to see a return on them. If sales continue rising while promotional and overhead spending absorb the benefit, higher volumes will do less for earnings than investors might expect.

The mix figures add another detail. Prestige and Above products accounted for 45.0% of Q2 volumes, down from 47.1% a year earlier. Their sales contribution slipped from 56.9% to 56.4%. The premium portfolio is growing, but other parts of the business have also been expanding. It would be too generous to describe the aggregate sales record as proof that the whole portfolio is moving upmarket faster.

The Rs 29 crore adjustment needs time to prove itself

ABD’s presentation sets out a more profitable picture after removing the effects of global supply-chain disruption. Management estimates that excluding Rs 29 crore of these costs would lift Q2 EBITDA to Rs 172 crore, against the reported Rs 143 crore. The adjusted margin would be 14.9%, and PAT Rs 91 crore instead of Rs 69 crore.

That calculation helps explain what has held earnings back. It is not a promise of what the next quarter will earn.

Some disruption costs may ease. Spending on brands and people is likely to remain part of running and expanding the business. The two should not be grouped together as if both will disappear. For now, the reported result is the firmer starting point; the adjusted figures show the improvement management believes is possible.

A few quarters of better reported margins would give that view more weight. Another set of large adjustments would leave the question open.

New facilities bring costs as well as savings

ABD started commercial operations at its Moradabad bottling facility in October, with initial annual capacity of six million cases. It says the assets cost about Rs 70 crore to acquire, followed by roughly Rs 40 crore of upgrades. The Rangapur malt distillery, also commissioned in October, involved around Rs 75 crore and annual capacity of approximately four million bulk litres.

The attraction is straightforward. Producing more internally could reduce external sourcing and franchise costs and improve service in important markets. At higher utilisation, those savings could make a meaningful difference to margins.

But the money has been committed before the full benefit is visible. Depreciation and financing costs must be covered, and capacity has to be used. October’s sales help the utilisation case; demand after the festive period will tell us more about its durability.

Better operating cash flow has not stopped debt rising

There is progress in the cash-flow statement. H1 operating cash flow reached Rs 269 crore, up from Rs 147 crore. Investing activities used Rs 350 crore, however, leaving an Rs 81 crore gap before financing. This is a subtraction of the two disclosed cash-flow totals, not a company-reported free-cash-flow figure.

Meanwhile, current and non-current borrowings together rose from Rs 1,146 crore in March to Rs 1,388 crore in September, excluding leases. Cash and equivalents declined from Rs 129 crore to Rs 81 crore. ABD’s net debt to trailing EBITDA increased from 1.7 times to 2.2 times, and ROCE fell from 19.7% to 18.4%.

These figures do not cancel out the operating improvement. They show that expansion is drawing heavily on the balance sheet. The next stage needs to bring better returns from the capital already invested, with cash generation doing more of the funding.

ABD’s valuation calls for more than another sales record

At 3:52 pm IST on 3 November, 5paisa displayed a price of Rs 694.55, market capitalisation of about Rs 19,427 crore and a P/E of 85.1 times. These are the provider’s dated figures, not a live 4 November quote or a verified forward valuation.

At that multiple, volume growth alone is a thin reason to buy. Investors are paying for the possibility that a larger brand portfolio and greater control over production will eventually produce much stronger earnings. October supports the demand assumption. It says little yet about the margin and cash assumptions.

My reading is positive on the sales update, but cautious on using it to justify the share price. In the next results, I would look first for stronger reported margins and evidence that debt is stabilising. Continued sales growth accompanied by weaker cash conversion would be less reassuring. ABD has shown it can sell more; shareholders now need to see how much of that growth it can keep.